BDR- Blackhills Diagnostic Resources

Name

BDR- Blackhills Diagnostic Resources

Legal name

BLACKHILLS DIAGNOSTIC RESOURCES S.L.U.

Website

https://bdrdiagnostics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF), Release Testing & Batch Certification (QC) (HLAGADAC)

Keywords

• In vitro diagnostics
• Genetic testing kits
• HLA typing assays
• Triplet repeat disorders
• Clinical PCR reagents

Headquarters

HQ city

Zaragoza

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. IVD Kit Sales (Own Brand): Sale of CE-IVD certified diagnostic kits under own brand names (Genvinset®, Adellgene®) to clinical laboratories and healthcare providers. Products are manufactured in-house.
2. OEM Products: Manufacturing and selling products under OEM (original equipment manufacturer) arrangements, where BDR produces diagnostic kits for other brands.
3. NGS Solutions: Complete NGS solutions including library preparation, sequencing, and bioinformatics analysis software for clinical laboratories.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Blackhills Diagnostic Resources (BDR) researches, develops, manufactures in-house, and sells CE-IVD certified in vitro diagnostic kits for human genetic testing, organized under the Genvinset® Real Time PCR brand, the Adellgene® fragment analysis brand, and the NGS on!® Whole Exome sequencing solution, complemented by proprietary bioinformatics software. Products are sold both under BDR's own brand and on an OEM basis to clinical laboratories and healthcare specialists across national and international markets.

Product overview

BDR offers a portfolio of in vitro diagnostic (IVD) products organized under three main brands: Genvinset® (Real Time PCR/qPCR kits), Adellgene® (fragment analysis kits), and NGS (Next Generation Sequencing solutions). The Genvinset® brand includes HLA typing assays (B27, B51, B57, A29, C*06, Celiac-related alleles, Narcolepsy, Behçet) and pharmacogenomics tests (DPYD). The Adellgene® brand covers triplet repeat disorders including Huntington Disease, Friedreich's Ataxia, Fragile X Syndrome, Myotonic Dystrophy, and Spinocerebellar Ataxias (SCAs), complemented by the Adellgene® Triplet Repeat Calculator bioinformatics software. NGS offerings include Whole Exome sequencing with proprietary bioinformatics tools. All products are CE-IVD certified and manufactured in-house for both own-brand and OEM distribution.

Differentiator

Problem solved

Functional benefit

Brands

• Genvinset®: Product line for detection of genetic markers by Real Time PCR technology
• Adellgene®
• NGS on!® Whole Exome
• Bioinformatics

Products and services

• Genvinset® Real Time PCR Kit Line Family of CE-IVD Real Time PCR kits for detection of genetic markers associated with HLA-related pathologies (ankylosing spondylitis, Behçet's disease, abacavir hypersensitivity, celiac disease, narcolepsy, psoriasis) and pharmacogenomic testing (DPYD for fluoropyrimidine toxicity), sold to clinical laboratories and healthcare specialists.
• Adellgene® Fragment Analysis Kit Line Family of CE-IVD semi-automated kits using fluorescent fragment analysis for quantitative determination of triplet repeat expansions associated with Huntington Disease, Friedreich's Ataxia, Fragile X Syndrome, Myotonic Dystrophy Type 1, and autosomal dominant Spinocerebellar Ataxias (SCAs), sold to clinical genetics laboratories.
• NGS on!® Whole Exome End-to-end NGS solution including library preparation, sequencing, and proprietary bioinformatics analysis for comprehensive whole exome genetic analysis, targeted at clinical laboratories performing advanced genetic diagnostics.
• Adellgene® Triplet Repeat Calculator Proprietary bioinformatics data management software that converts fragment analysis allele sizes (base pairs) from GeneMapper™ output into corresponding triplet repeat counts and generates final diagnostic reports for Adellgene® kit users in transplant and genetics laboratories.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Four partnerships are on record, tiered supporting and core.

• Cámara de Comercio de EspañasupportingGTM or Marketing Partner · 1 January 2024Beneficiary of 2024 international certification grants under the 'Mentoring and SME Internationalization Support' program. Part of Spain's Recovery, Transformation, and Resilience Plan (PRTR). Program aims to strengthen internationalization capabilities and expand to new export markets.
• Annar Healthcare TechnologiescoreChannel Partner/ Reseller/ Distributor · 1 September 2023Exclusive distributor in Colombia for BDR's fragment analysis technology products. Annar Healthcare Technologies has published educational videos about using fragment analysis technology for diagnosing rare neurological disorders. Dr. Daniel Salgado serves as Field Application Specialist providing product training.
• Diagnóstica LongwoodcoreStrategic or Co-development Partner · 27 January 2023Joint R&D project beneficiary with 500,235€ grant from Government of Aragón. Project: 'Research on a new non-invasive method based on HLA genotyping from circulating mRNA for early detection of organ transplant rejection.' Both companies co-lead the project under ORDEN EPE/71/2023.
• Grupo San Valero (Universidad San Jorge, SEAS)supportingGTM or Marketing Partner · 1 January 2023Collaboration partner for digital transformation and employee training programs. Programs 'Generación Digital: Agentes del Cambio' and 'Transformación Digital para Directivos de PYMEs' funded by Next Generation EU funds. Berta Sáez, rector of Universidad San Jorge, leads these initiatives for SME competitiveness.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Cepheid (Danaher): Operates the GeneXpert molecular diagnostics platform used in clinical laboratories for genetic and infectious disease testing, an alternative infrastructure that competes for IVD budgets BDR targets.
• Abbott Molecular: Large-scale molecular diagnostics business with HLA typing and pharmacogenomics assays, representing a scaled incumbent competing for the same clinical laboratory customers as BDR.
• Promega Corporation: Supplies PCR, qPCR, and capillary electrophoresis reagents used in genetic testing workflows, overlapping with BDR's qPCR and fragment-analysis chemistries at the reagent layer.
• QIAGEN: Global molecular diagnostics leader with broad PCR, NGS, and sample-prep portfolios used in HLA typing and genetic disease testing, providing competitive pressure across BDR's full technology stack.
• Revvity (formerly PerkinElmer): Provides genetic screening and IVD reagents including HLA and rare-disease assays, comparable in product category though at materially larger scale than BDR.
• Thermo Fisher Scientific: Offers the Ion Torrent NGS platform plus HLA typing and pharmacogenomics IVD kits (e.g., DPYD), overlapping with BDR's Genvinset DPYD and NGS on! Whole Exome offerings.

Direct peers

• Asuragen (Bio-Techne): Develops PCR and fragment-analysis kits for repeat-expansion disorders (Fragile X, Huntington) and oncology, with CE-IVD-marked products in the same niche as BDR's Adellgene range.
• Elucigene Diagnostics: Specializes in fragment-analysis and PCR-based IVD kits for genetic disorders including cystic fibrosis and Friedreich's Ataxia, closely overlapping BDR's Adellgene product line in technology and target indications.
• Bio-Rad Laboratories: Bio-Rad offers fragment-analysis-based kits for triplet repeat disorders (Huntington, Fragile X, Myotonic Dystrophy) and HLA typing via its ddPCR and QX200/real-time PCR platforms, directly overlapping BDR's Adellgene and Genvinset product lines.
• Vienna Lab Diagnostics: Specialist European IVD company producing CE-marked genetic diagnostic kits for hereditary diseases, hemoglobinopathies, and HLA typing, comparable in scale and product mix to BDR's niche genetic IVD portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bdr-blackhills-diagnostic-resources

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BDR- Blackhills Diagnostic Resources